Smartkarma Newswire

Align Technology, Inc. (ALGN)

220.45 USD -5.60 (-2.48%) Volume: 1.19M

Align Technology, Inc.’s stock price is currently at 220.45 USD, experiencing a decrease of 2.48% this trading session with a trading volume of 1.19M. Despite its robust performance, the stock has seen a year-to-date (YTD) decline of 19.54%, indicating potential investment opportunities for discerning investors.

Latest developments on Align Technology, Inc.

Align Technology, Inc. (ALGN) recently reported their Q2 earnings, beating expectations but also lowering their sales view for 2024. This led to a drop in their stock price as consumers shifted towards lower-priced clear braces. Despite an increase in EPS, the company announced a lower revenue forecast for the year. Analysts downgraded the stock, causing shares to gap down. Additionally, Align Technology introduced the iTero™ Design Suite to enhance 3D printing capabilities for dental professionals. The company’s stock price movements today reflect these key events and market reactions.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

T. Rowe Price Group, Inc. (TROW)

112.08 USD -3.41 (-2.95%) Volume: 1.97M

T. Rowe Price Group, Inc.’s stock price stands at 112.08 USD, experiencing a decline of -2.95% this trading session with a trading volume of 1.97M, yet showing a positive YTD change of +4.08%, indicating a resilient performance in the market.

Latest developments on T. Rowe Price Group, Inc.

T. Rowe Price Group‘s stock price movements today are influenced by the company’s strong performance in the second quarter of 2024. The company reported a jump in profits, driven by a boost from the market rally. Despite a three-year streak of outflows, the CEO is optimistic about a turnaround in 2025. T. Rowe Price beat earnings estimates in Q2, with assets under management rising year over year. However, the stock underperformed compared to competitors, despite daily gains. The company’s investment advisory fees rose, but revenue missed estimates, leading to a dip in share prices. Overall, T. Rowe Price’s financial performance and strategic initiatives are closely watched by Wall Street forecasters, shaping investor expectations for the future.

A look at T. Rowe Price Group, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking at the Smartkarma Smart Scores for T. Rowe Price Group, the company seems to have a solid long-term outlook. With high scores in Dividend and Resilience, it indicates that the company is well-positioned to provide stable returns to investors over time. The Growth score, although not as high, still shows potential for future expansion and development.

While the Value and Momentum scores are not as strong, the overall picture for T. Rowe Price Group appears to be positive. As a financial services holding company that provides investment advisory services, T. Rowe manages a diverse range of investment portfolios, which may contribute to its Resilience score. Investors may find T. Rowe Price Group to be a reliable option for long-term investment opportunities.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Franklin Resources, Inc. (BEN)

23.08 USD -0.56 (-2.37%) Volume: 6.47M

Franklin Resources, Inc.’s stock price is currently at 23.08 USD, experiencing a drop of -2.37% this trading session with a trading volume of 6.47M, reflecting a significant YTD decrease of -22.52%; a key point for investors monitoring BEN’s market performance.

Latest developments on Franklin Resources, Inc.

Franklin Resources, Inc. has reported a climb in their fiscal third-quarter results, driven by higher fees despite facing net outflows. The company’s earnings beat estimates, with earnings per share of $0.32 falling short, but revenue of $2.12 billion exceeding expectations. Franklin Resources also saw an increase in stock holdings by investment firms like Russell Investments Group Ltd. and Vanguard Group Inc. Additionally, the company made headlines for partnering with SBI Holdings to launch a digital asset management company in Japan. Despite some losses, Franklin Resources stock outperformed competitors, showcasing steady growth amid tech investments.

A look at Franklin Resources, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Franklin Resources, also known as Franklin Templeton Investments, is a company that provides investment advisory services to a wide range of clients. According to Smartkarma Smart Scores, the company has a strong dividend score of 5, indicating a positive outlook for investors looking for steady income. Additionally, Franklin Resources scored well in the value category with a score of 4, suggesting that the company may be undervalued compared to its competitors.

Looking at the long-term outlook, Franklin Resources received a growth score of 3, resilience score of 3, and momentum score of 2. While the company may not be experiencing significant growth or momentum currently, its strong dividend and value scores indicate stability and potential for long-term returns. Investors seeking a reliable investment option may find Franklin Resources to be a favorable choice based on these Smartkarma Smart Scores.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Principal Financial Group, Inc. (PFG)

81.53 USD -2.89 (-3.42%) Volume: 1.83M

Principal Financial Group, Inc.’s stock price stands at 81.53 USD, experiencing a decline of -3.42% this trading session with a trading volume of 1.83M, yet showing resilient growth with a YTD increase of +3.64%, indicative of its steady performance in the stock market.

Latest developments on Principal Financial Group, Inc.

Today, Principal Financial Group announced their second quarter 2024 earnings with an EPS of $1.49 and revenue of $386.1 million. Despite a slight miss in earnings, the company saw a rise in revenues year over year. This news led to fluctuations in the stock price, with some investors like Bessemer Group Inc. acquiring shares while others, like Sei Investments Co., increasing their holdings. Additionally, Citigroup raised the price target for Principal Financial stock to $70.00, indicating confidence in the company’s performance. Overall, the market responded positively to Principal Financial‘s financial results, showcasing the company’s growth and profitability in the current market environment.

A look at Principal Financial Group, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Principal Financial Group, Inc. offers a range of financial products and services to businesses, individuals, and institutional clients. According to Smartkarma Smart Scores, the company has received moderate scores across the board, with a Value, Dividend, Growth, and Momentum score of 3, and a Resilience score of 4. This indicates a stable long-term outlook for Principal Financial, with a strong focus on resilience in the face of market challenges.

With a balanced overall outlook based on the Smartkarma Smart Scores, Principal Financial is positioned to continue providing reliable financial solutions to its clients. The company’s emphasis on retirement solutions, life and health insurance, wellness programs, and investment and banking products aligns with its consistent performance in key areas. Investors can expect Principal Financial to maintain a steady course in the financial services industry, supported by its solid Resilience score.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

ResMed Inc. (RMD)

197.04 USD -11.30 (-5.42%) Volume: 1.9M

ResMed Inc.’s stock price stands at 197.04 USD, reflecting a dip of -5.42% this trading session, with a trading volume of 1.9M. Despite the drop, the stock showcases a positive YTD change of +14.54%, indicating overall robust performance.

Latest developments on ResMed Inc.

ResMed Inc. stock experienced a rise today, outperforming the market as investors eagerly awaited the company’s quarterly earnings report. With Wall Street expecting earnings growth, anticipation was high leading up to the release. American International Group Inc. decreased its stock holdings in ResMed Inc., while investment firm Natixis maintained a substantial $2.78 million position in the company. The market was abuzz with speculation as traders kept a close eye on ResMed’s performance, which ultimately led to the stock’s positive movement today.

ResMed Inc. on Smartkarma

Analysts at Baptista Research have provided bullish coverage on ResMed Inc on Smartkarma, highlighting the company’s strong financial performance in the third quarter of 2024. The company showed robust top-line and double-digit bottom-line growth, driven by high demand for their devices globally, as well as growth in their Software as a Service business and masks and accessories segment. Despite tough comparisons from the previous year, ResMed’s results have impressed analysts with their continued growth trajectory.

Furthermore, Baptista Research also published a report on ResMed’s potential expansion of sleep awareness and population health management strategies, pointing out the company’s strong execution in the second quarter of fiscal year 2024. The double-digit growth in both devices and Software as a Service business reflects ResMed’s efforts to address the significant global issue of sleep-related conditions affecting over 2 billion people. Analysts are optimistic about ResMed’s growth prospects as they continue to innovate and address the growing demand for sleep solutions.

A look at ResMed Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

ResMed Inc. has a mixed outlook based on the Smartkarma Smart Scores. While the company scores well in growth and momentum, indicating potential for future expansion and positive stock performance, it falls short in value and resilience. This suggests that investors may need to carefully consider the company’s financial health and stability in the long term. The dividend score falls in the middle, indicating a moderate level of dividend payout for shareholders.

Overall, ResMed Inc. shows promise in terms of growth and momentum, which could attract investors looking for opportunities in the medical equipment sector. However, the lower scores in value and resilience may warrant further investigation into the company’s financial standing and ability to withstand market fluctuations. With a focus on developing and selling equipment for sleep disordered breathing, ResMed Inc. continues to operate in a niche market with potential for growth and innovation.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Biogen Inc. (BIIB)

211.17 USD -16.27 (-7.15%) Volume: 2.22M

Biogen Inc.’s stock price stands at 211.17 USD, experiencing a significant drop of 7.15% this trading session with a trading volume of 2.22M. The pharmaceutical giant’s stock performance continues to struggle, reflecting a year-to-date percentage change of -18.39%, highlighting potential investment concerns.

Latest developments on Biogen Inc.

Biogen’s stock price experienced fluctuations today following a series of key events. The rejection of an Alzheimer’s drug developed in partnership with Eisai by European regulators led to a significant drop in the company’s shares. Additionally, a failed midphase trial for a neurological disorder drug in collaboration with Sage Therapeutics prolonged the wait for a new treatment option, causing further uncertainty for investors. The decision to scrap the development of the essential tremor drug after trial failure also impacted Biogen’s stock price. These developments have raised concerns among analysts and investors about the company’s future earnings potential and strategic direction.

A look at Biogen Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Biogen Inc. has received a solid overall outlook based on the Smartkarma Smart Scores. With high scores in value and momentum, the company is positioned well for long-term success. Despite a lower score in resilience, Biogen’s focus on developing therapies for neurology, oncology, and immunology is expected to drive growth in the future.

Although Biogen may not be a top choice for dividend investors due to its lower score in that category, its strong performance in value and momentum bodes well for the company’s future prospects. With a diverse range of products addressing various diseases, including multiple sclerosis, non-hodgkin’s lymphoma, and rheumatoid arthritis, Biogen is poised to continue making significant strides in the healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

DexCom, Inc. (DXCM)

64.00 USD -43.85 (-40.66%) Volume: 53.77M

DexCom, Inc.’s stock price plummets to $64.00, a drastic decrease of 40.66% in the recent trading session and a staggering 48.42% YTD, with an overwhelming trading volume of 53.77M, reflecting a turbulent year for DXCM investors.

Latest developments on DexCom, Inc.

Dexcom Inc is experiencing a significant drop in its stock price after announcing a revenue miss, leading to a more than 40% plunge in shares, the worst day on record for the company. The stock plummeted as the company cut its sales forecast, spooking investors and causing a nearly 40% tumble in share value. With hints of competitive pressures impacting the company’s earnings, Dexcom faces challenges ahead as it slashes its full-year sales forecast, prompting a major setback for the medical device maker. Analysts are questioning whether GLP-1 drugs are creating headwinds for Dexcom and other similar companies, contributing to the stock’s decline. Despite short-term challenges, the market growth prospects remain strong for Dexcom, but the company must navigate through the current uncertainties to regain investor confidence.

DexCom, Inc. on Smartkarma

Analysts at Baptista Research are bullish on Dexcom Inc, a company known for its continuous glucose monitoring (CGM) technology. In their research report titled “DexCom Inc.: Why Are We Bullish On This Med-Tech Player Despite the Highly Evident Challenges Ahead? – Major Drivers”, they highlight the strong performance of Dexcom in the first quarter of 2024. The surge in organic revenue growth of 25% compared to the previous year is attributed to the increasing demand for Dexcom CGM, driven by its leading product performance and unique user experience. The launch of G7 in the U.S. has allowed Dexcom to attract new prescribers and expand its impact in primary care, leading to a growing demand from individuals with diabetes.

Another report by Baptista Research, titled “DexCom Inc: Solid Market Penetration in Basal and Hypo Non-insulin markets & International Expansion Is Catalyzing Future Growth! – Major Drivers”, discusses Dexcom Inc‘s strong market penetration in basal and hypo non-insulin markets, along with its international expansion efforts. The company’s Fourth quarter and Fiscal year 2023 earnings call revealed a 24% organic revenue growth, surpassing $700 million in organic revenue from the previous year. These achievements have positioned Dexcom for future growth and success in the medical device industry. The analysts remain bullish on Dexcom’s prospects based on these positive developments.

A look at DexCom, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Dexcom Inc has a mixed outlook for the long term. While the company scores well in terms of growth, resilience, and momentum, its value and dividend scores are lower. This suggests that Dexcom may have strong potential for future growth and resilience in the market, but investors should not expect high dividends or necessarily see the company as undervalued.

Dexcom Inc is a medical device company specializing in continuous glucose monitoring systems for individuals with diabetes. With a focus on innovation and technology, the company has received positive scores in growth, resilience, and momentum. This indicates that Dexcom may continue to expand its market presence and maintain stability in the face of challenges. However, investors should consider the lower scores in value and dividend when assessing the overall long-term outlook for the company.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma